These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32690263)

  • 21. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
    J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
    J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Kovela S; Brindisi M; Osswald HL; Sekhara Reddy B; Agniswamy J; Wang YF; Aoki M; Hattori SI; Weber IT; Mitsuya H
    ChemMedChem; 2018 Apr; 13(8):803-815. PubMed ID: 29437300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
    Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
    Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
    Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
    Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
    J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
    Lockbaum GJ; Leidner F; Rusere LN; Henes M; Kosovrasti K; Nachum GS; Nalivaika EA; Ali A; Yilmaz NK; Schiffer CA
    ACS Infect Dis; 2019 Feb; 5(2):316-325. PubMed ID: 30543749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants.
    Ma L; Wen J; Dong B; Zhou J; Hu S; Wang J; Wang Y; Zhu M; Cen S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants.
    Zhu M; Ma L; Zhou H; Dong B; Wang Y; Wang Z; Zhou J; Zhang G; Wang J; Liang C; Cen S; Wang Y
    Eur J Med Chem; 2020 Jan; 185():111866. PubMed ID: 31734023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
    Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants.
    Meng S; Gao Y; Qiang G; Hu Z; Shan Q; Wang J; Wang Y; Mou J
    Bioorg Med Chem Lett; 2024 Mar; 101():129651. PubMed ID: 38342391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.
    Ghosh AK; Osswald HL; Glauninger K; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2016 Jul; 59(14):6826-37. PubMed ID: 27389367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Kulkarni S; Anderson DD; Hong L; Baldridge A; Wang YF; Chumanevich AA; Kovalevsky AY; Tojo Y; Amano M; Koh Y; Tang J; Weber IT; Mitsuya H
    J Med Chem; 2009 Dec; 52(23):7689-705. PubMed ID: 19746963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.
    Parai MK; Huggins DJ; Cao H; Nalam MN; Ali A; Schiffer CA; Tidor B; Rana TM
    J Med Chem; 2012 Jul; 55(14):6328-41. PubMed ID: 22708897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands.
    Ghosh AK; Kovela S; Sharma A; Shahabi D; Ghosh AK; Hopkins DR; Yadav M; Johnson ME; Agniswamy J; Wang YF; Hattori SI; Higashi-Kuwata N; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2022 May; 17(9):e202200058. PubMed ID: 35170223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of novel HIV-1 protease inhibitors containing pyrrolidine-derived P2 ligands to combat drug-resistant variant.
    Zhou H; Ma L; Dong B; Wang J; Zhang G; Wang M; Cen S; Zhu M; Shan Q; Wang Y
    Eur J Med Chem; 2023 Jul; 255():115389. PubMed ID: 37120996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.